Commentary: The case for universal varicella immunization

Pediatric Infectious Disease Journal

Volumn 25, Issue 1, 2006, Pages 45-46

  Seward, Jane F ^a   Orenstein, Walter A ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE;

CENTRAL AMERICA; CLINICAL TRIAL; EUROPE; HERPES ZOSTER; HUMAN; IMMUNIZATION; NOTE; PHYSICIAN; PRIORITY JOURNAL; SOUTH AMERICA; UNITED STATES; VACCINATION; VARICELLA ZOSTER VIRUS;

EID: 33644838120     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Pinot de Moira A, Nardone A. Varicella zoster virus vaccination policies and surveillance strategies in Europe. Euro Surveill. 2005;10:43-45.
2. Wharton M. The epidemiology of varicella-zoster virus infections. Infect Dis Clin North Am. 1996;10:571-581.
3. Meyer PM, Seward IF, Jumaan AO, Wharton M. Varicella mortality: trends before vaccine licensure in the United States, 1970-1994. J Infect Dis. 2000;182:383-390.
4. Galil G, Brown C, Lin F, Seward J. Hospitalizations for varicella in the United States, 1988-1999. Pediatr Infect Dis J. 2002;21:931-934.
5. Davis MM, Patel MS, Gebremariam A. Decline in varicella-related hospitalizations and expenditures for children and adults after introduction of varicella vaccine in the United States. Pediatrics. 2004;114:786-792.
6. Nguyen H, Jumaan AO, Seward JF. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med. 2005;352:450-458.
7. Brisson M, Edmunds WJ, Gay NJ, Law B, De Serres G. Modelling the impact of immunization on the epidemiology of varicella zoster virus. Epidemiol Infect. 2000;125:651-669.
8. Seward JF, Watson BM, Peterson CL, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA. 2002;287:606-611.
9. Kuter B, Matthews H, Shinefield H, et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J. 2004;23:132-137.
10. Vazquez M, LaRussa PS, Gershon AA, et al. Effectiveness over time of varicella vaccine. JAMA. 2004;291:851-855.
11. Black S, Shinefield H, Ray P, et al. Postmarketing evaluation of the safety and effectiveness of varicella vaccine. Pediatr Infect Dis J. 1999;18:1041-1046.
12. Hardy I, Gershon AA, Steinberg SP, LaRussa P. The incidence of zoster after immunization with live attenuated varicella vaccine: a study in children with leukemia. N Engl J Med. 1991;325:1545-550.
13. Jumaan AO, Yu O, Jackson LA, Bohlke K, Galil K, Seward JF. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J Infect Dis. 2005;191:2002-2007.
14. Yih WK, Brooks DR, Lett SM, et al. The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003. BMC Public Health. 2005;5:68.
15. Jumaan AO, Seward JF, Wooten K, Chen J, Singleton JA. Varicella and herpes zoster surveillance in the U.S., 1970-1994. Presented at the 41st Annual Meeting of the Infectious Diseases Society of America, October 9-12, 2003, San Diego, CA. Alexandria, VA: Infectious Diseases Society of America; 2003. Abstract 899.
16. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271-2284.
17. Zhou F, Herpaz R, Jumanan AO, et al. Impact of varicella vaccine on health care utilization. JAMA. 2005;294:797-780.